Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
- cell therapy
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 6607
IPSCIO Record ID: 3489
And MaXcess instruments provide access to the spine in a manner that affords direct visualization and our nerve monitoring systems assist surgeons in avoiding critical nerves. Our MaXcess system consists of instrumentation and specialized implants that provide maximum access to the spine with minimal soft tissue disruption. MaXcess has a split blade design consisting of three blades that can be positioned to build the surgical exposure in the shape and size specific to the surgical requirements rather than the fixed tube design of other minimally invasive surgical systems. MaXcessâ€™ split blade design also provides expanded access to the spine, which allows surgeons to perform surgical procedures using instruments that are similar to those used in open procedures but with a significantly smaller incision. The ability to use familiar instruments reduces the learning curve and facilitates the adoption of our products. Our systemâ€™s illumination of the operative corridor aids in providing surgeons with direct visualization of the patientâ€™s anatomy, without the need for additional technology or other special equipment.
IPSCIO Record ID: 3091
With the settlement, Licensee will pay Licensor a one-time fee and the Licensor will not receive any additional payments for sales of AbraxaneÂ®, or any other nabÂ®-Paclitaxel product in the United States or globally. Licensee will acquire a fully-paid up, exclusive, world-wide license to select Licensor's U.S. and foreign patents for AbraxaneÂ®.
At issue was Licenseeâ€™s alleged infringement of Licensorâ€™s patent for the nanoparticulate formulation of the breast cancer drug Abraxane.
A federal jury in the U.S. District Court for the District of Delaware agreed with that contention, and ordered the Company Licensee to pay an upfront fee and ongoing royalty.
IPSCIO Record ID: 312594
In April 2020, the Court granted in part Licensorâ€™s motion and entered a final judgment awarding royalties on Licenseeâ€™s sales of Yescarta* from December 13, 2019 through the expiration of the Patent in August 2024.
Yescarta is a trademark of Licensee. Yescarta, a CAR T cell therapy, involves (i) harvesting T cells from the patientâ€™s blood, (ii) engineering T cells to express cancer-specific receptors, (iii) increasing the number of engineered T cells and (iv) infusing the functional cancer-specific T cells back into the patient.